Divaka Perera1, Tim Clayton2, Mark C Petrie3, John P Greenwood4, Peter D O'Kane5, Richard Evans2, Mark Sculpher6, Theresa Mcdonagh7, Anthony Gershlick8, Mark de Belder9, Simon Redwood10, Gerald Carr-White10, Michael Marber10. 1. National Institute for Health Research Biomedical Research Centre and British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine and Sciences, King's College London, London, United Kingdom. Electronic address: Divaka.Perera@kcl.ac.uk. 2. Clinical Trials Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom. 3. Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom. 4. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, United Kingdom. 5. Royal Bournemouth and Christchurch Hospital, United Kingdom. 6. Centre for Health Economics, University of York, United Kingdom. 7. King's College Hospital, London, United Kingdom. 8. Biomedical Research Unit, University Hospitals of Leicester, Leicester, United Kingdom. 9. The James Cook Hospital, Middlesbrough, United Kingdom. 10. National Institute for Health Research Biomedical Research Centre and British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine and Sciences, King's College London, London, United Kingdom.
Abstract
OBJECTIVES: Evaluate whether PCI in combination with optimal medical therapy (OMT) will reduce all-cause death and hospitalization for HF compared to a strategy of OMT alone. BACKGROUND: Ischemic cardiomyopathy (ICM) is the most common cause of heart failure (HF) and is associated with significant mortality and morbidity. Surgical revascularization has been shown to improve long-term outcomes in some patients, but surgery itself carries a major early hazard. Percutaneous coronary intervention (PCI) may allow a better balance between risk and benefit. METHODS: REVIVED-BCIS2 is a prospective, multi-center, open-label, randomized controlled trial, funded by the National Institute for Health Research in the United Kingdom. Follow-up will be for at least 2 years from randomization. Secondary outcomes include left ventricular ejection fraction (LVEF), quality of life scores, appropriate implantable cardioverter defibrillator therapy and acute myocardial infarction. Patients with LVEF ≤35%, extensive coronary disease and demonstrable myocardial viability are eligible for inclusion and those with a myocardial infarction within 4 weeks, decompensated HF or sustained ventricular arrhythmias within 72 h are excluded. A trial of 700 patients has more than 85% power to detect a 30% relative reduction in hazard. RESULTS: A total of 400 patients have been enrolled to date. CONCLUSIONS: International guidelines do not provide firm recommendations on the role of PCI in managing severe ICM, because of a lack of robust evidence. REVIVED-BCIS2 will provide the first randomized data on the efficacy and safety of PCI in ICM and has the potential to inform guidelines pertaining to both revascularization and HF. (Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure [REVIVED-BCIS2]; NCT01920048) (REVascularisation for Ischaemic VEntricular Dysfunction; ISRCTN45979711).
RCT Entities:
OBJECTIVES: Evaluate whether PCI in combination with optimal medical therapy (OMT) will reduce all-cause death and hospitalization for HF compared to a strategy of OMT alone. BACKGROUND:Ischemic cardiomyopathy (ICM) is the most common cause of heart failure (HF) and is associated with significant mortality and morbidity. Surgical revascularization has been shown to improve long-term outcomes in some patients, but surgery itself carries a major early hazard. Percutaneous coronary intervention (PCI) may allow a better balance between risk and benefit. METHODS: REVIVED-BCIS2 is a prospective, multi-center, open-label, randomized controlled trial, funded by the National Institute for Health Research in the United Kingdom. Follow-up will be for at least 2 years from randomization. Secondary outcomes include left ventricular ejection fraction (LVEF), quality of life scores, appropriate implantable cardioverter defibrillator therapy and acute myocardial infarction. Patients with LVEF ≤35%, extensive coronary disease and demonstrable myocardial viability are eligible for inclusion and those with a myocardial infarction within 4 weeks, decompensated HF or sustained ventricular arrhythmias within 72 h are excluded. A trial of 700 patients has more than 85% power to detect a 30% relative reduction in hazard. RESULTS: A total of 400 patients have been enrolled to date. CONCLUSIONS: International guidelines do not provide firm recommendations on the role of PCI in managing severe ICM, because of a lack of robust evidence. REVIVED-BCIS2 will provide the first randomized data on the efficacy and safety of PCI in ICM and has the potential to inform guidelines pertaining to both revascularization and HF. (Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure [REVIVED-BCIS2]; NCT01920048) (REVascularisation for Ischaemic VEntricular Dysfunction; ISRCTN45979711).
Authors: Renato D Lopes; Karen P Alexander; Susanna R Stevens; Harmony R Reynolds; Gregg W Stone; Ileana L Piña; Frank W Rockhold; Ahmed Elghamaz; Jose Luis Lopez-Sendon; Pedro S Farsky; Alexander M Chernyavskiy; Ariel Diaz; Denis Phaneuf; Mark A De Belder; Yi-Tong Ma; Luis A Guzman; Michel Khouri; Alessandro Sionis; Derek J Hausenloy; Rolf Doerr; Joseph B Selvanayagam; Aldo Pietro Maggioni; Judith S Hochman; David J Maron Journal: Circulation Date: 2020-08-29 Impact factor: 29.690
Authors: Jimmy Zheng; Paul A Heidenreich; Shun Kohsaka; William F Fearon; Alexander T Sandhu Journal: J Am Coll Cardiol Date: 2022-03-08 Impact factor: 27.203
Authors: Derek S Chew; Patricia A Cowper; Hussein Al-Khalidi; Kevin J Anstrom; Melanie R Daniels; Linda Davidson-Ray; Yanhong Li; Robert E Michler; Julio A Panza; Ileana L Piña; Jean L Rouleau; Eric J Velazquez; Daniel B Mark Journal: Circulation Date: 2022-01-19 Impact factor: 29.690
Authors: Simon C Y Chow; Randolph H L Wong; Peter S Y Yu; Jacky Y K Ho; Joyce W Y Chan; Micky W T Kwok; Song Wan; Takuya Fujikawa; Malcolm J Underwood Journal: J Thorac Dis Date: 2020-03 Impact factor: 2.895